[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Seen as Attractive Ahead of 2026 Pipeline Catalysts, BofA Says",
    "summary": "Bristol-Myers Squibb (BMY) offers a favorable risk/reward heading into 2026, supported by four to si",
    "url": "https://finnhub.io/api/news?id=7abc3ceafc29efd132eb345c41c4d196b4ece0d651a27039513da5e239d56886",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765816500,
      "headline": "Bristol-Myers Squibb Seen as Attractive Ahead of 2026 Pipeline Catalysts, BofA Says",
      "id": 137795454,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (BMY) offers a favorable risk/reward heading into 2026, supported by four to si",
      "url": "https://finnhub.io/api/news?id=7abc3ceafc29efd132eb345c41c4d196b4ece0d651a27039513da5e239d56886"
    }
  },
  {
    "ts": null,
    "headline": "BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?",
    "summary": "BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.",
    "url": "https://finnhub.io/api/news?id=1d4a90b0200d0f97c62ae38bef46dd9a306144d0cf979a0704ceb7ef8d7748a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765809120,
      "headline": "BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?",
      "id": 137792667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.",
      "url": "https://finnhub.io/api/news?id=1d4a90b0200d0f97c62ae38bef46dd9a306144d0cf979a0704ceb7ef8d7748a0"
    }
  },
  {
    "ts": null,
    "headline": "Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More",
    "summary": "Pre-Market Stock Futures: Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard on Friday as investors began a big rotation last week out of the AI stocks that have led the market higher since ChatGPT was introduced over three years ... Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More",
    "url": "https://finnhub.io/api/news?id=770b09fa4b7f70a9939394549885a20f208971ae2ce2c56084618c09214b7aef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765808179,
      "headline": "Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More",
      "id": 137792211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pre-Market Stock Futures: Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard on Friday as investors began a big rotation last week out of the AI stocks that have led the market higher since ChatGPT was introduced over three years ... Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More",
      "url": "https://finnhub.io/api/news?id=770b09fa4b7f70a9939394549885a20f208971ae2ce2c56084618c09214b7aef"
    }
  },
  {
    "ts": null,
    "headline": "How Investors May Respond To Bristol Myers (BMY) Dividend Hike And Oncology Pipeline Momentum",
    "summary": "In recent days, Bristol Myers Squibb’s board approved a 1.6% increase in its quarterly common dividend to US$0.63 per share for February 2026 and reaffirmed its preferred dividend, while the company also secured FDA Priority Review for an Opdivo label expansion in advanced classical Hodgkin lymphoma and new approval for Breyanzi in relapsed or refractory marginal zone lymphoma. Together with extensive hematology data at the ASH meeting and progress in AI-enabled drug discovery...",
    "url": "https://finnhub.io/api/news?id=bb5f5fae9b68ab8a3bdca665e40cb022c3d8b79f77c988112d99b1b6141e902f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765789632,
      "headline": "How Investors May Respond To Bristol Myers (BMY) Dividend Hike And Oncology Pipeline Momentum",
      "id": 137792669,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "In recent days, Bristol Myers Squibb’s board approved a 1.6% increase in its quarterly common dividend to US$0.63 per share for February 2026 and reaffirmed its preferred dividend, while the company also secured FDA Priority Review for an Opdivo label expansion in advanced classical Hodgkin lymphoma and new approval for Breyanzi in relapsed or refractory marginal zone lymphoma. Together with extensive hematology data at the ASH meeting and progress in AI-enabled drug discovery...",
      "url": "https://finnhub.io/api/news?id=bb5f5fae9b68ab8a3bdca665e40cb022c3d8b79f77c988112d99b1b6141e902f"
    }
  }
]